Stability of End-of-life Preferences: a Systematic Review of the Evidence
Overview
Authors
Affiliations
Importance: Policies and practices that promote advance care planning and advance directive completion implicitly assume that patients' choices for end-of-life (EOL) care are stable over time, even with changes in health status.
Objective: To systematically evaluate the evidence on the stability of EOL preferences over time and with changes in health status.
Evidence Review: We searched for longitudinal studies of patients' preferences for EOL care in PubMed, EMBASE, and using citation review. Studies restricted to preferences regarding the place of care at the EOL were excluded.
Findings: A total of 296 articles were assessed for eligibility, and 59 met inclusion criteria. Twenty-four articles had sufficient data to extract or calculate the percentage of individuals with stable preferences or the percentage of total preferences that were stable over time. In 17 studies (71%) more than 70% of patients' preferences for EOL care were stable over time. Preference stability was generally greater among inpatients and seriously ill outpatients than among older adults without serious illnesses (P < .002). Patients with higher education and who had engaged in advance care planning had greater preference stability, and preferences to forgo therapies were generally more stable than preferences to receive therapies. Among 9 of the 24 studies (38%) assessing changes in health status, no consistent relationship with preference changes was identified.
Conclusions And Relevance: Considerable variability among studies in the methods of preference assessment, the time between assessments, and the definitions of stability preclude meta-analytic estimates of the stability of patients' preferences and the factors influencing these preferences. Although more seriously ill patients and those who engage in advance care planning most commonly have stable preferences for future treatments, further research in real-world settings is needed to confirm the utility of advance care plans for future decision making.
Anticoagulation at the end of life: whether, when, and how to treat.
Parks A Hematology Am Soc Hematol Educ Program. 2024; 2024(1):348-354.
PMID: 39644066 PMC: 11665705. DOI: 10.1182/hematology.2024000559.
Leveraging the electronic health record to identify delivery of goal-concordant care.
Auriemma C, Song A, Walsh L, Han J, Yapalater S, Bain A medRxiv. 2024; .
PMID: 39399021 PMC: 11469341. DOI: 10.1101/2024.09.24.24314226.
[Ethical boundary decisions in intensive care medicine].
Scherr B, Buehler P Inn Med (Heidelb). 2024; 65(10):967-975.
PMID: 39311946 PMC: 11452514. DOI: 10.1007/s00108-024-01781-5.
Paying for advance care planning in medicare: Impacts on care and spending near end of life.
Chen A, Li J J Health Econ. 2024; 98:102921.
PMID: 39277926 PMC: 11631671. DOI: 10.1016/j.jhealeco.2024.102921.
Pandemic Effects on Stability of End-of-Life Preferences and Patient-Surrogate Dyad Congruence.
Song M, Paul S, Pelkmans J, Ward S J Pain Symptom Manage. 2024; 67(6):571-579.e2.
PMID: 38514021 PMC: 11088979. DOI: 10.1016/j.jpainsymman.2024.03.016.